During the height of the Covid crisis US Pharmaceutical company Gilead was involved in late stage clinical trial for its breakthrough anti-viral treatment Remdesivir which was thought to show promising efficacy in treating Covid-19.
With unprecedented media interest the company was under pressure to put up spokespeople in different markets to update on progress. We were engaged to prepare these opinion leaders and make sure they were media ready. Furthermore, as the science was quite complicated, it was our job to ensure they were able to communicate the key messages so they were easily understood by a consumer audience. Over 30 spokespeople were trained remotely across Europe and the Middle East in less than a month.
